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Abstract
Background: Mean platelet volume (MPV) is a strong predictor of impaired angiographic 
reperfusion and 6-month mortality in ST-elevation myocardial infarction (MI) treated with 
primary percutaneous coronary intervention (PCI). No data is available for other platelet vo-
lume indices: platelet distribution width (PDW) and platelet large cell ratio (P-LCR). The aim 
was to assess the impact of 3 platelet volume indices on long-term prognosis in patients treated 
with primary PCI in acute MI. 
Methods: This prospective study enrolled 538 patients who underwent primary PCI in acute 
MI. Admission blood samples were measured for MPV, PDW, and P-LCR. The patients were 
followed-up a mean period of 26 ± 11 months with regard to cardiac death, non-fatal rein-
farction, re-PCI or coronary artery bypass grafting. 
Results: Kaplan-Meier survival analysis showed a significantly higher 26-month mortality 
rate in patients with high MPV (≥ 11.7 fL) than in those with low MPV (< 11.7 fL) (14.6% 
vs. 5.5%, p = 0.0008). Similar findings were related to high P-LCR (≥ 38.1%) vs. low P-LCR 
(< 38.1%) — mortality 13.8% vs. 5.8%, p = 0.0025. Higher PDW values (≥ 16 fL) correlated 
with higher mortality rate as compared to PDW < 16 fL (17.4% vs. 6.3%, p = 0.0012). PDW 
was found to be an independent prognostic factor for cardiac mortality and composite endpoint. 
Conclusions: Mean platelet volume, platelet distribution width and platelet large cell ratio 
measured on admission are strong, independent prognostic factors in PCI-treated acute MI. 
(Cardiol J 2013; 20, 5: 491–498)
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Introduction
Platelet activation plays a pivotal role for the 
initiation of acute coronary syndromes. Platelet 
size has been shown to correlate with their fun-
ction. Large platelets are considered metabolically 
and enzymatically more reactive than smaller ones 
[1]. Increased mean platelet volume (MPV) is 
associated with extent of slow coronary flow [2]. 
MPV has been reported as increased in unstable 
angina pectoris and myocardial infarction (MI) [3]. 




2013, Vol. 20, No. 5, pp. 491–498
DOI: 10.5603/CJ.2013.0134
Copyright © 2013 Via Medica
ISSN 1897–5593
events is associated with worse outcome, as well 
as with higher risk of recurrent stroke [4, 5]. It 
has also been recognized as an independent risk 
factor for MI, but not for coronary artery disease 
prevalence [6, 7]. Measured at 6 months after acute 
MI, MPV has been shown to predict recurrent MI 
and death in 2-year follow up [8]. In ST-segment 
elevation MI treated with percutaneous coronary 
intervention (PCI), MPV has been observed to be 
a strong, independent factor of impaired angiographic 
reperfusion and 6-month mortality [9]. Platelet 
size has also been suggested to be correlated with 
the development of restenosis after successful 
coronary angioplasty [10].
Currently, automated cell counters enable 
routine availability of extended panel of platelet 
volume indices (PVI) beyond MPV, e.g. platelet 
distribution width (PDW) and platelet large cell ra-
tio (P-LCR); there is, however, limited information 
on their clinical importance. The P-LCR indicates 
the percentage of large platelets with a volume 
> 12 fL. The share of platelets > 12 fL in the total 
platelet number is presented as percentage and the 
normal range is 15–35%. An increase in P-LCR 
may indicate the presence platelet aggregates, 
microerythrocytes and giant platelets.
The PDW is calculated as the platelet distribu-
tion width measured at 20% relative height of the 
total height of the curve depicting the distribution 
of them. An increased PDW is an indication for the 
anisocytosis of platelets. The normal range for 
PDW is 9 to 14 fL.
Thus, we designed the study to assess the 
impact of PVI, measured on admission, on long-
-term prognosis in patients after MI treated with 
primary percutaneous intervention. 
Methods
Study population
The study group consisted of 538 consecutive 
patients with acute MI hospitalized in our depart-
ment. The diagnosis of acute ST-elevation MI was 
established according to the ESC/ACC consensus 
[11]. Mean prehospital delay was 192 ± 106 (range 
20–900) min. Blood samples were drawn on admis-
sion, before revascularization procedure. Coronary 
angiography and subsequent angioplasty were 
performed according to the standard femoral tech-
nique with mean door-to-needle time of 40 min. 
300 mg of aspirin was administered before blood 
sampling, and continued thereafter at the daily dose 
of 75 mg. A loading dose of 300 mg clopidogrel was 
given pre-procedurally and continued for 6 weeks 
at the dose of 75 mg. The glycoprotein IIb/IIIa 
inhibitor — abciximab — was administered during 
the revascularization procedure at the operator’s 
discretion in 62% (334/538) of cases, according to 
the patient’s high risk. Baseline demographic and 
clinical data are shown in Table 1. 
The study protocol was approved by the local 
ethics committee. The study complies with the 
Declaration of Helsinki. Informed consent has been 
obtained from all subjects. 
Follow up 
The patients were followed up for a mean time 
of 790 ± 335 days. The following clinical events 
were defined as endpoints: cardiac death (no non-
-cardiac death occurred), non-fatal re-infarction 
and repeat revascularization either percutaneous 
(PCI) or surgical (CABG, coronary artery bypass 
grafting). A combined endpoint (Composite), defi-
ned as occurrence of any endpoint: cardiac death 
or reinfarction or repeat revascularization, was also 
analyzed. Long-term follow-up data were obtained 
from all patients using available medical records 
and by telephone or personal contact.
Laboratory methods
Blood samples were drawn into standardized 
test tubes containing dipotassium edetic acid 
(EDTA). All samples were analyzed on Sysmex 
K-4500 automated cell counter (Sysmex Corpo-
ration Japan, Koebe, Japan), with time to result 
approximately 1 min. Three platelet volume in-
Table 1. The characteristics of study group.





Previous MI 57 (15.9%)
Total cholesterol [mg/dL] 210 ± 48
LDL [mg/dL] 135 ± 43
HDL [mg/dL] 41 ± 11
Triglycerides [mg/dL] 162 ± 105
Hemoglobin [g/dL] 13.6 ± 1.7
WBC [n × 103/mm3] 9.9 ± 3.2
Platelet count [n × 103/mm3] 225 ± 69
Mean platelet volume [fL] 10.8 ± 1.2
Platelet distribution width [fL] 13.4 ± 2.5
Platelet large cell ratio [%] 33.2 ± 15.7
MI — myocardial infarction; LDL — low density lipoprotein; 
HDL — high density lipoprotein; WBC — white blood count
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dices: MPV, PDW and P-LCR, as well as platelet 
count were assessed. PDW and P-LCR data were 
obtained for 512 patients only. PDW was measu-
red between 20th and 80th percentile of platelet 
histogram. P-LCR was defined by the cell counter 
manufacturer as the percentage of platelets larger 
than the constant cut-off of 12 fL. 
Statistical analysis
Continuous variables are expressed as mean 
± SD, whereas categorical variables are presen-
ted as absolute values and percentages. Patients 
were divided into groups based on MPV, PDW and 
P-LCR values. The cut-off values were determined 
by ROC analysis. Group differences of categorical 
variables were analyzed by a c2 test with Yates 
correction for continuity while group differences 
of continuous variables were evaluated by ANOVA. 
Correlation between PVI and platelet count 
was calculated with Spearman’s rank correlation 
coefficient. Survival rates were calculated by 
Kaplan-Meier curve analysis, with the differences 
in survival assessed using the log-rank test. The 
impact of abciximab administration was analyzed 
with Cox proportional-hazards regression. Mul-
tivariate analysis was performed with logistic 
regression, stepwise method. Differences were 
considered significant at the value of p < 0.05 
(2-tailed). MedCalc version 7.3.0.1 (Belgium, 
Frank Schoonjans) statistical software was used 
to perform all statistical calculations. 
Results
The clinical events during follow-up 
There were 91 clinical events during follow-up 
(more than one event could be recoreded in indi-
vidual patient), with event-free course in 452/538 
(84%) patients. Mortality rate was 7.6% (41/538). 
21/538 (3.9%) patients had the recurrence of in-
farction, 5.3% underwent repeat revascularization 
with PCI (21/538) or CABG (8/538). The composite 
endpoint thus occurred in 16% (86/538) of patients.
Predictive values of platelet volume indices
There was a negative correlation between the 
analyzed platelet volume indices and platelet count 
— MPV (r = –0.418; p < 001), PDW (r = –0.441, 
p < 0.01), and P-LCR (r = –0.410, p < 0.001) 
(Table 2), whereas there was no relationship with 
other clinical and laboratory data (Table 3). 
As opposed to platelet count, all 3 PVI were 
highly predictive for cardiac mortality and compo-
site clinical endpoint.
Receiver operating characteristics (ROC) 
were used to identify cut-off values for prediction 
Table 3. Relationship of platelet volume indices with age, biochemical and haematological parameters 
according to Spearman’s rank correlation.
Mean platelet  
volume: p
Platelet distribution  
width: p
Platelet large  
cell ratio: p
Age 0.603 (NS) 0.221 (NS) 0.367 (NS)
Total cholesterol 0.211 (NS) 0.575 (NS) 0.815 (NS)
Low density lipoprotein 0.090 (NS) 0.079 (NS) 0.445 (NS)
High density lipoprotein 0.726 (NS) 0.275 (NS) 0.847 (NS)
Triglycerides 0.830 (NS) 0.637 (NS) 0.909 (NS)
Haemoglobin 0.432 (NS) 0.067 (NS) 0.637 (NS)
Red blood count 0.757 (NS) 0.069 (NS) 0.715 (NS)
White blood count 0.274 (NS) 0.171 (NS) 0.284 (NS)
Efficacy of reperfusion 0.790 (NS) 0.983 (NS) 0.985 (NS)
NS — non-significant; efficacy of reperfusion was measured according to TIMI scale
Table 2. Correlation between platelet volume indices and platelet count.
Arithmetic  
mean




Mean platelet volume [fL] 10.8 ± 1.2 –0.418 < 0.001
Platelet distribution width [fL] 13.4 ± 6.3 –0.441 < 0.001
Platelet large cell ratio [%] 33 ± 16 –0.410 < 0.001
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of the occurrence of endpoints. The best cut-off 
values for prediction of the composite endpoint 
were 11.7 fL for MPV, 16 fL for PDW and 38.1% 
for P-LCR. The area under the ROC curve for MPV 
was 0.61 (95% CI 0.57–0.65). The value of 11.7 
had a positive predictive value (PPV) of 27.7% and 
negative predictive value (NPV) of 87.4%. The area 
under the PDW ROC curve was also 0.61 (95% CI 
0.57–0.65), with PPV of the value 16 fL as low as 
36.4% but NPV of 87.2%. The area under the ROC 
curve for P-LCR was 0.63 (95% CI 0.58–0.67). The 
PPV was 27.1% while the NPV was 88%. High 
MPV, defined as ≥ 11.7 fL, was observed in 22.9% 
(123/538) of patients, high PDW determined as 
≥ 16 fL was present in 13.5% (69/512), whereas high 
P-LCR (≥ 38.1%) in 25.2% (129/512) of patients.
For cardiac mortality, the best cut-off value for 
MPV was 10.9 fL, with the area under ROC curve 
0.65 (95% CI 0.61–0.69), PPV of only 11.9%, but 
NPV of 95.5%. For PDW the cut-off was 13.3 fL, 
the area under ROC curve was 0.64 (95% CI 
0.60–0.68), PPV 11.8% and NPV 95.3%. The cut-off 
value for P-LCR was 31.7%, with the area under 
ROC curve of 0.65 (95% CI 0.61–0.69), PPV of 
11.5% and NPV of 96%. 
According to the index event angiography, 
in 67% (362/538) patients a single critical lesion 
was found; 25% (135/538) had 2-vessel disease 
and 8% (41/538) suffered from 3-vessel disease. 
There were no statistically significant differences 
between the number of vessels involved and the 
platelet indices (p = 0.67 for MPV, p = 0.49 for 
PDW and p = 0.63 for P-LCR). 
Platelet volumes and clinical characteristics of 
subpopulations defined according to cut-off values 
of platelet parameters.
According to ROC analysis and derived 
threshold values, high and low risk subsets were 
identified for 3 platelet parameters. The demogra-
phic and clinical data are presented in Table 3. There 
where no differences in age, gender, concomitant 
diabetes mellitus, hypertension, history of smo-
king, hemoglobin concentration nor white blood 
cell count between the groups. Previous history of 
MI was related with higher values of PVI, reaching 
statistical significance of p = 0.031 and p = 0.043 
for MPV and PDW, respectively. A relationship 
was also found between PVI and lipid profile, 
with a statistically significant, positive correlation 
between P-LCR and serum concentration of high-
-density cholesterol (HDL) (p = 0.022), as well as 
low-density cholesterol (LDL) (p = 0.025). MPV 
correlated with HDL concentration (p = 0.021). 
The relationship between PDW and HDL and 
LDL cholesterol concentration, as well as between 
MPV and LDL cholesterol concentration did not 
reach statistical significance, although a positive 
trend was observed (p = 0.085, p = 0.107 and 
p = 0.124, respectively) (Table 4). 
Survival analysis
Mortality rate in the follow-up period was sig-
nificantly higher in patients with high MPV values 
than in those with low MPV values (14.6% [18/123] 
vs. 5.5% [23/415], p < 0.001). Similarly, the survi-
val in patients with high PDW was worse than in 
those with low PDW (mortality 17.4% [12/69] vs. 
6.3% [28/443], p = 0.0012). High values of P-LCR 
were also correlated with higher mortality rate 
compared to low values of P-LCR (13.8% [18/130] 
vs. 5.8% [22/382], p = 0.0028). The prevalence of 
non-fatal reinfarction was insignificantly higher in 
patients with high PDW (7.2% vs. 3.2%, p = 0.084). 
Repeat coronary revascularization, either percuta-
neous or surgical, was performed in 5.3% (29/538) 
of patients, and the prevalence was higher in pa-
tients with high PDW (10.1% vs. 4.5%, p = 0.034) 
and high P-LCR (8.5% vs. 4.2%, p = 0.041). The 
composite endpoint correlated with MPV (26.8% 
for high MPV values vs. 12.8% for low MPV, 
p < 0.001), PDW (34.8% for high PDW vs. 12.9% 
for low PDW, p < 0001), as well as with P-LCR 
(26.9% for high values vs. 12% for low values, 
p = 0.0001). The results of the survival analysis 
are shown in Figure 1 and Table 5. 
In Cox proportional-hazards regression analy-
sis, abciximab use in clinically evaluated high-risk 
patients was not found to significantly contribute to 
the prediction of the unfavourable clinical course 
and was not included in the model. 
Multivariate analysis
Multivariate analysis was applied to determi-
ne the prognostic usefulness of platelet volume 
parameters as compared with standard clinical 
variables available during the initial assessment of 
patients with acute MI. PVI were expressed herein 
as dichotomous variables (high vs. low). 
The univariate analysis showed the following 
factors to contribute to the prediction of cardiac 
mortality: age — OR 1.05 (95% CI 1.02–1.09); 
MPV — OR 2.92 (95% CI 1.52–5.61); PDW — OR 
3.12 (95% CI 1.50–6.48); P-LCR — OR 2.63 (95% 
CI 1.36–5.08); red blood count — OR 0.50 (95% 
CI 0.27–0.93); white blood count — OR 1.14 (95% 
CI 1.04–1.25); ejection fraction — OR 0.9614 (95% 
CI 0.92–0.99); efficacy of reperfusion expressed 
by TIMI scale — OR 0.61 (95% CI 0.44–0.84). 
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Table 4. Characteristics of subgroups defined by ROC curve analysis.
Mean platelet volume (MPV) P
MPV < 11.7 (n = 415) MPV ≥ 11.7 (n = 123)
Age [years] 58 ± 10 59 ± 10 0.706
Male 289 (69.6%) 83 (67.5%) 0.650
Diabetes 48 (11.6%) 13 (10.6%) 0.820
Hypertension 128 (30.8%) 47 (38.2%) 0.102
Smoking 122 (29.4%) 28 (22.8%) 0.591
Previous MI 36 (8.7%) 19 (15.5%) 0.031
Total cholesterol [mg/dL] 208 ± 48 212 ± 48 0.389
LDL-cholesterol [mg/dL] 132 ± 42 139 ± 42 0.124
HDL-cholesterol [mg/dL] 40 ± 10 43 ± 13 0.021
Triglycerides [mg/dL] 162±104 159±83 0.790
Hemoglobin [g/L] 13.6±2.7 13.4±2.1 0.316
WBC [n × 103/mm3] 9.9±3.1 10.2±3.5 0.346
Platelet count [n × 103/mm3] 238±69 179±48 < 0.001
Platelet distribution width (PDW) P
PDW < 16 (n = 443) PDW ≥ 16 (n = 69)
Age [years] 58 ± 10 60 ± 9 0.185
Male 309 (69.7%) 47 (68.1%) 0.784
Diabetes 46 (9.8%) 8 (11.3%) 0.759
Hypertension 143 (30.6%) 23 (32.4%) 0.887
Smoking 123 (26.3%) 16 (22.5%) 0.417
Previous MI 38 (8.1%) 12 (16.9%) 0.043
Total cholesterol [mg/dL] 206 ± 47 209 ± 43 0.659
LDL-cholesterol [mg/dL] 130 ± 42 140 ± 35 0.107
HDL-cholesterol [mg/dL] 40 ± 10 43 ± 13 0.085
Triglycerides [mg/dL] 163 ± 104 156 ± 82 0.535
Hemoglobin [g/dL] 13.6 ± 1.8 13.2 ± 1.6 0.090
WBC [n × 103/mm3] 10 ± 3.2 9.6 ± 3.4 0.370
Platelet count [n × 103/mm3] 234 ± 69 168 ± 50 < 0.001
Platelet large cell ratio (P-LCR) P
P-LCR < 38.1 (n = 383) P-LCR ≥ 38.1 (n = 129)
Age [years] 58 ± 10 59 ± 10 0.524
Male 269 (70%) 87 (67.4%) 0.552
Diabetes 40 (10.5%) 14 (10.8%) 0.318
Hypertension 117 (30.6%) 49 (38%) 0.467
Smoking 103 (27%) 36 (27.9%) 0.762
Previous MI 32 (8.4%) 19 (14.7%) 0.064
Total cholesterol [mg/dL] 204 ± 46 214 ± 48 0.070
LDL-cholesterol [mg/dL] 129 ± 41 140 ± 41 0.025
HDL-cholesterol [mg/dL] 40 ± 10 43 ± 13 0.022
Triglycerides [mg/dL] 163 ± 107 157 ± 82 0.590
Haemoglobin [g/dL] 13.6 ± 1.6 13.5 ± 2 0.398
WBC [n × 103/mm3] 9.9 ± 3.1 10.2 ± 3.4 0.482
Platelet count [n × 103/mm3] 239 ± 71 181 ± 47 < 0.001
MI — myocardial infarction; WBC — white blood count
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Figure 1. Platelet volume indices and event-free survi-
val in 2-year follow-up: Kaplan-Meier survival curves; 
HR — hazard ratio; 95% CI — 95% confidence interval; 
p — statistical significance.
In the multivariate analysis age, PDW, red blood 
count, white blood count and efficacy of reperfusion 
were found to be independent prognostic factors of 
cardiac mortality in a 2-year follow up (p < 0.001) 
(Table 6).
No variables were shown to be independent 
prognostic factors for reinfarction, nor for the need 
of another revascularization procedure.
For the prediction of occurrence of the compo-
site endpoint, age — OR 1.03 (95% CI 1.01–1.06); 
MPV — OR 2.50 (95% CI 1.53–4.10); PDW — OR 
3.61 (95% CI 2.05–6.37); P-LCR — OR 2.69 (95% 
CI 1.64–4.41) and efficacy of reperfusion — OR 
0.72 (95% CI 0.54–0.96) were proved significant 
in the univariate analysis. In the multivariate 
logistic regression, only age, PDW and efficacy of 
reperfusion were found to independently predict 
the occurrence of cardiac death, reinfarction or 
need for another revascularization procedure 
(p < 0.001) (Table 7). 
Discussion
The main findings of our study indicate that 
platelet parameters, easily available from auto-
mated cell counters, are powerful predictors of 
unfavourable clinical course in patients with MI 
treated with primary percutaneous intervention. 
For the first time, PDW and P-LCR were identified 
as prognostic predictors after MI. Importantly, 
their prognostic value was stronger than that 
previously reported of MPV. Additional prediction 
of reinfarction and repeat revascularization using 
PDW became thus feasible. 
Baseline platelet volume indices
In the present study, the groups seem to be 
well balanced in terms of most of the conventional 
risk factors of acute coronary events [12]. How-
ever, larger platelets are detected in patients with 
higher values of LDL and HDL cholesterol. This 
is consistent with some previous findings [13], 
although other studies did not prove such cor-
relation [5, 7]. In the present study, PVI are also 
raised in a small (10.2%) subset of patients with 
past history of MI compared to those with the first 
episode of an acute coronary event; in the literature 
there is also evidence of protracted circulation of 
larger platelets after acute MI [6, 7, 13]. The pre-
sence of larger platelet size in patients with history 
of the coronary artery disease may be interpreted 
as a consequence of platelet consumption at the 
site of coronary lesion and subsequent stimulation 
of the bone marrow [2]. Platelets produced under 
conditions of stimulated thrombocytopoiesis, called 
“stress” platelets by Tong at al. [14], tend to show 
increased MPV. Similarly, there is strong evidence 
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Table 5. The relationship of platelet parameters with post-infarction clinical course: Kaplan-Meier  
survival analysis.
Mean platelet  
volume
Platelet distribution  
width
Platelet large  
cell ratio
Cardiac death p < 0.001 
HR = 2.73 
95% CI = 1.70–7.50
p = 0.0012 
HR = 2.88 
95% CI = 1.84–11.80
p = 0.0025 
HR = 2.51 
95% CI = 1.48–6.33
Reinfarction p = 0.42 (NS) 
HR = 1.47 
95% CI = 0.54–4.37
p = 0.084 
HR = 2.39 
95% CI = 0.85–12.38
p = 0.42 (NS) 
HR = 1.48 
95% CI = 0.53–4.43
Revascularization p = 0.218 (NS) 
HR = 1.63 
95% CI = 0.72–4.24
p = 0.034 
HR = 2.46 
95% CI = 1.10–10.90
p = 0.041 
HR = 2.18 
95% CI = 1.04–6.12
Composite endpoint 
Death + reinfarction  
+ revascularization)
p < 0.001 
HR = 2.24 
95% CI = 1.61–4.53
p < 0.001 
HR = 2.99 
95% CI = 2.60–9.88
p < 0.001 
HR = 2.42 
95% CI = 1.76–4.91
CI — confidence interval; HR — hazard ratio; NS — non-significant; p — statistical significance
Table 6. Impact of variables significant in the univariate analysis on the prediction of cardiac mortality: 
multivariate logistic regression.
Factor RC OR 95% CI P
Platelet distribution width [fL] 1.08 2.96 1.23–7.09 0.015
White blood count [n × 103] 0.13 1.13 1.03–1.26 0.015
Age [years] 0.04 1.04 1.00–1.09 0.013
Efficacy of reperfusion –0.49 0.61 0.41–0.90 0.013
Red blood count [n × 106] –0.67 0.51 0.27–0.98 0.044
RC — regression coefficient; OR — odds ratio; 95% CI — 95% confidence interval; p — statistical significance; efficacy of reperfusion  
assessed with TIMI scale 0–3
Table 7. Impact of variables significant in the univariate analysis on the prediction of the composite 
endpoint: multivariate logistic regression.
Factor RC OR 95% CI P
Platelet distribution width [fL] 1.15 3.15 1.74–5.70 < 0.001
Age [years] 0.03 1.04 1.01–1.06 0.020
Efficacy of reperfusion –0.38 0.69 0.51–0.93 0.014
RC — regression coefficient; OR — odds ratio; 95% CI — 95% confidence interval; p — statistical significance; efficacy of reperfusion  
assessed with TIMI scale 0–3
of an increase in platelet size after CABG, following 
the destruction of platelets in the extracorporeal 
circulation [15]. In accordance with previous reports, 
in the present study a strong negative correlation 
between platelet count and size was noticed [9]. 
Clinical outcomes
Platelet on-treatment hyperreactivity, measu-
red by aggregation following agonists stimulation, 
has been proved to influence the prognosis in 
patients after PCI [16]. 
Although postinfarction antiplatelet treat-
ment was uniform, no information is available on 
patients’ previous use of antiplatelet drugs. No 
literature data, however, suggest any impact of 
antiplatelet drugs on platelet volume [17].
Moreover, the analysis of the impact of other 
compounds was not included in this study, with 
special emphasis on insulin as opposed to oral hy-
poglycemic treatment in diabetic patients, though 
it should be stated that the correlation of platelet 
volume and insulin dependence was denied by 
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some authors [18]. Recently, Jindal et al. [19] 
reported that diabetics in general, and diabetics 
with microvascular complications in particular 
have higher values of PDW, in our study we did 
not observed any difference between prevalence 
of diabetes mellitus between patients divided 
according to cut-off PDW value. Lack of inclusion 
of any data on beta-blockers or statins intake — 
as known predictors of mortality beyond hospital 
phase — makes the results of multivariate ana-
lysis not as informative as possible [20]. EDTA 
is recognized to provide the best conditions 
of anticoagulation for both routine clinical and 
research laboratory measurement of platelet 
volume [21, 22]. However, previous studies re-
ported platelet swelling when EDTA was used 
as an anticoagulant. It was also implied that the 
swelling may be associated with different EDTA 
amounts in the tubes [3]. To minimize the ef-
fect, all measurements were performed within 
1 h from blood collection, since according to recent 
findings, the increase in MPV can be diminished 
up to approximately < 0.5 fL, as long as the analy-
sis is performed within 2 h after venipuncture [6]. 
The study protocol included single time PVI 
measurement. In the setting of acute ST elevation MI 
patients one cannot exclude influence of confounding 
factors on platelet function parameters. PVI were not 
re-evaluated on discharge, which might have been 
useful to better define their prognostic implications. 
Furthermore, the measurement of PVI can 
only indirectly extrapolate the presence of circu-
lating larger platelets, while direct measurement, 
available with more advanced techniques like flow 
cytometry, might be a more sensitive marker in 
determining high-risk patients in relation to the 
hyperactivity that large platelets show despite the 
treatment with antiplatelet agents [23].
Conclusions
Our findings indicate that not only MPV, but 
also other PVI, namely PDW and P-LCR, can serve 
as useful prognostic factors for long-term mortality 
in patients after acute MI. PDW was found to be one 
of independent risk factors of cardiac mortality, as 
well as of the occurrence of either death, recurrent 
MI or need for another revascularization procedure. 
Thus, in the management of the acute phase of 
coronary events, PVI may become a valuable con-
tribution to identification of high-risk patients, who 
might require more potent antiplatelet therapy. 
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